Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it ...

Healthcare and medical technology company Johnson & Johnson (JNJ) has reported first-quarter financial results that beat Wall ...

For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson ...

Reese Marketos played the role of government prosecutor in a False Claims Act case about alleged off-label use of an HIV drug ...

Johnson & Johnson (NYSE:JNJ), on Tuesday, reported a first-quarter 2025 adjusted EPS of $2.77, up 2.2% year over year, beating the consensus of $2.60. The pharmaceutical giant reported sales of $ ...

Q1 adjusted EPS of $2.77 beat estimates; cancer drug Darzalex sales jumped 20.3% ... % or 4.2 operationally to $13.90 billion. Also Read: Johnson & Johnson, Protagonist Tout Positive Results ...

He also trains his eye on the American media itself, noting ways that reporters at times portrayed the FDA’s actions against drugmakers as tougher than they really were. Harris’ book provides a ...

Bryan Johnson, a biohacking enthusiast, has spent millions trying to slow aging. Instead, his use of the drug rapamycin may ...

J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers.

The Dark Secrets of Johnson & Johnson.” Erythropoietin — also known as EPO — is mostly remembered as the drug that cyclist Lance Armstrong dishonestly used to win seven Tours de France.

The chief executive of Johnson & Johnson has warned that potential ... Joe Wolk said the administration’s investigation into drug imports, widely seen as a first step toward imposing levies ...